Bio-IT World Contributed Commentary | Every day counts when it comes to saving lives and generating revenue, especially when you’re trying to bring a drug, treatment, or diagnostic tool to market. Unfortunately, these processes often take a lot longer and cost a lot more than initially expected.

Bio-IT World | As we head into 2020, we at Bio-IT World would like to take a moment and reflect on the groundbreaking achievements from this past year. In that spirit, here are the top 10 stories of 2019, ranked in order of popularity.

Bio-IT World Contributed Commentary | Many enterprise network security people intuitively put everything behind a firewall—even though it has been well-established that firewalls are big hindrance to high-speed data flows. There are a few reasons of poor data mobility and thus low utilization.

Bio-IT World | Stem cell biotech company Novoheart has been bioengineering miniature human hearts as a platform for drug discovery and development for several to pharmaceutical firms, notably for human conditions without a good animal model for preclinical testing. Novoheart’s thumb-sized human “heart-in-a-jar” models can both contract and eject blood-like fluid, making it possible to measure how well the heart is pumping.

Bio-IT World Contributed Commentary | Productivity in the pharmaceutical industry is rapidly declining. This crisis has created a need to re-think the way clinical trials are conceived, designed and conducted. As such, artificial intelligence is poised to transform the industry.

Bio-IT World | Illumina and Pacific Biosciences of California today announced that they have mutually agreed to terminate their merger agreement. In accordance with the merger agreement, Illumina will pay Pacific Biosciences a termination fee of $98 million.

Bio-IT World Contributed Commentary | They say change is good, but it’s best if you have the ability to adapt. That’s certainly the case in the IT space, where digital transformation continues to drive rapid advancement across virtually every industry, and certainly in the life sciences. Here are some predictions and potential challenges to consider heading into next year.